Aggregator
China’s thriving forests are stockpiling vast amounts of carbon
From the archive: election special
Phenome-wide associations of human aging uncover sex-specific dynamics
How ‘miracle’ weight-loss drugs will change the world
Is there a ‘Goldilocks zone’ for paper length?
ChatGPT is transforming peer review — how can we use it responsibly?
India’s US$20-billion fertilizer subsidies could do more for farmers — here’s how
COP29: involve the IPCC in defining climate finance
AI-generated images threaten science — here’s how researchers hope to spot them
‘Invisible and uncharismatic’ fungi need taxonomy champions, too
Distributed peer review: how Ukraine has reaped the benefits and minimized the risks
How fungus-farming ants have nourished biology for 150 years
Western science diplomacy must rethink its biases and treat all partners equally
A spider’s windproof web
Global biodiversity convention comes up short on funding conservation
But negotiators approved a plan for raising money from companies that profit off genetic information from nature
Quest for a deeper theory of fundamental particles hits a curious snag
Most popular way to add more Higgs bosons to standard model goes mathematically haywire
Salmon carry nutrients—and pollutants—upriver when they spawn
Toxic contaminants may threaten some freshwater denizens, but pose little risk to humans
New approach to growing coronaviruses is research boon—but also raises safety concerns
Artificial virus receptors could help researchers find vaccines and treatments, but some worry about risk of lab leaks
Parkinson disease therapy: current strategies and future research priorities
Parkinson disease (PD) is the fastest growing neurological disorder globally and poses substantial management challenges owing to progressive disability, emergence of levodopa-resistant symptoms, and treatment-related complications. In this Review, we examine the current state of research into PD therapies and outline future priorities for advancing our understanding and treatment of the disease. We identify two main research priorities for the coming years: first, slowing the progression of the...
Pervasive biases in proxy genome-wide association studies based on parental history of Alzheimer's disease
Almost every recent Alzheimer's disease (AD) genome-wide association study (GWAS) has performed meta-analysis to combine studies with clinical diagnosis of AD with studies that use proxy phenotypes based on parental disease history. Here, we report major limitations in current GWAS-by-proxy (GWAX) practices due to uncorrected survival bias and nonrandom participation in parental illness surveys, which cause substantial discrepancies between AD GWAS and GWAX results. We demonstrate that the...